Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Epizyme, Inc. to Present at Upcoming Conferences in October

September 30, 2013

CAMBRIDGE, Mass., Sept. 30, 2013 /PRNewswire/ — Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in the following conferences in October:

    --  Leerink Swann Rare Disease Roundtable at Le Parker Meridien in New York
        on Wednesday, October 2 at 3:40 p.m. EDT. A live webcast will be
        available at this link or by visiting the Investor Center of the Epizyme
        website at www.epizyme.com. An archived replay of the webcast will be
        available on the Company's website for 30 days after the conference.
    --  Cell Symposia, Cancer Epigenomics at the Hotel Melia in Sitges, Spain on
        Monday, October 7 at 6:25 p.m. EDT. The discussion will focus on histone
        methyltransferase inhibitors as therapeutics for genetically defined
        cancers.
    --  Novalix Conference 2013 - Biophysics in Drug Discovery Symposium at
        Palais Universitaire in Strasbourg, France on Wednesday, October 16 at
        2:00 p.m. EDT. The discussion will focus on protein methyltransferase
        inhibitors as personalized cancer therapeutics.
    --  AACR-NCI-EORTC International Conference on Molecular Targets and Cancer
        Therapeutics at the Hynes Convention Center in Boston on Monday, October
        21 at 8:00 a.m. EDT. The discussion will focus on epigenetic regulators
        as therapeutic targets.
    --  SciBX Summit on Innovation in Drug Discovery and Development at the
        Colonnade Boston Hotel in Boston on October 29 - 30 as part of a panel
        discussion titled "Epigenetics' Second Wind."

About Epizyme, Inc.

Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme’s targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.

For more information, visit http://www.epizyme.com and connect with us on Twitter at @EpizymeRx.

SOURCE Epizyme, Inc.


Source: PR Newswire